2025 Q3 -tulosraportti
113 päivää sitten
‧23 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 11 111 | - | - | ||
| 18 074 | - | - | ||
| 11 371 | - | - | ||
| 1 493 | - | - | ||
| 2 732 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenThe NGAL test can now be used for an incredible number of different diseases, but research has also been conducted into whether the test can also be used for pregnant women. The result was positive. They emphasize in the article that it is very positive that the test can be used early in pregnancy. So when the test for adults becomes FDA approved, it will certainly also become a permanent part of treatment for pregnant women. https://pmc.ncbi.nlm.nih.gov/articles/PMC9708734/
·12 t sittenIt is clear who owns and who does not own bioporto, a bit pathetic 😏
·8 t sittencreos If you put aside the unsubstantiated angles, then I would like to participate in a factual debate. Let me know when you are ready.- ·1 päivä sittenI just want to remind you that there is a webcast on March 26 at 10:30 AM. I guess a new CFO will be presented on this occasion. Even if you cannot attend when it is broadcast, you can still ask questions and watch it when you have time. Registration necessary. https://www.inderes.dk/videos/bioporto-praesentation-af-fy-2025-resultater
- ·2 päivää sittenDear Progression When we talk about a penny stock, news can result in explosive movements. So I still believe that BP's price has not been determined yet. A piece of news can trigger explosive price movements. That's why I'm up around 4 kr. within a year. The final price target - relatively! - I cannot comment on. But quite simply: IF! the adult test comes through, then we have a case that, age by age, generates increased revenues. A STUPID! estimate - if 1-22 years with the company's other revenues is around 45,000,000, then an adult approval - AS A STARTING POINT - will be an x5. AND - I AM NOT SURE ABOUT THIS: If the test is included in various studies/treatment paradigms, then there is probably no upper limit for value?! I have quite cautiously pointed to approx. 4,- kr. within a year. Because of PERSPECTIVE. And if that holds, then - quite easily - a lot will happen subsequently. WHAT BioPorto is worth right now and CAN!, can change very quickly. I have a calculation model behind this, but here are the more principal considerations. I will not encourage anyone to buy or sell - I just have a professional interest. Regards, Bagerbrød Regards, Bagerbrød·1 päivä sittenIf Bioporto meets deadlines, then it's up to the FDA. Fortunately, it will be an advantage for Bioporto that the NGAL test for children is the benchmark for future AKI tests, so for that reason, the adult test will be approved much faster than the children's test was.·1 päivä sitten · Muokattu3D Do you live in your alternative world? If BP meets deadlines? When BP doesn't meet a deadline, a new deadline comes, which may or may not be met. When the budget is not met, a new budget comes, which may be met. In 2025, we got 3 new "budgets" because the original expectations didn't hold water. 2 downward adjustments of financial targets. In 2024, it was said that the adult test should be sent for approval in 2026. In 2025, the target was then changed to "application in 2027". Will 2026 end with another downward adjustment of financial targets? Will there be another share issue, even though it's "taboo" in here among the BP faithful? We have hardly seen the last "delay".
·3 päivää sitten2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He has bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl took office on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his appointment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.
·6.3.Dear Bagerbrød I am a bit confused by your answer. I hold 30,000 pcs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
113 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenThe NGAL test can now be used for an incredible number of different diseases, but research has also been conducted into whether the test can also be used for pregnant women. The result was positive. They emphasize in the article that it is very positive that the test can be used early in pregnancy. So when the test for adults becomes FDA approved, it will certainly also become a permanent part of treatment for pregnant women. https://pmc.ncbi.nlm.nih.gov/articles/PMC9708734/·12 t sittenIt is clear who owns and who does not own bioporto, a bit pathetic 😏·8 t sittencreos If you put aside the unsubstantiated angles, then I would like to participate in a factual debate. Let me know when you are ready.
- ·1 päivä sittenI just want to remind you that there is a webcast on March 26 at 10:30 AM. I guess a new CFO will be presented on this occasion. Even if you cannot attend when it is broadcast, you can still ask questions and watch it when you have time. Registration necessary. https://www.inderes.dk/videos/bioporto-praesentation-af-fy-2025-resultater
- ·2 päivää sittenDear Progression When we talk about a penny stock, news can result in explosive movements. So I still believe that BP's price has not been determined yet. A piece of news can trigger explosive price movements. That's why I'm up around 4 kr. within a year. The final price target - relatively! - I cannot comment on. But quite simply: IF! the adult test comes through, then we have a case that, age by age, generates increased revenues. A STUPID! estimate - if 1-22 years with the company's other revenues is around 45,000,000, then an adult approval - AS A STARTING POINT - will be an x5. AND - I AM NOT SURE ABOUT THIS: If the test is included in various studies/treatment paradigms, then there is probably no upper limit for value?! I have quite cautiously pointed to approx. 4,- kr. within a year. Because of PERSPECTIVE. And if that holds, then - quite easily - a lot will happen subsequently. WHAT BioPorto is worth right now and CAN!, can change very quickly. I have a calculation model behind this, but here are the more principal considerations. I will not encourage anyone to buy or sell - I just have a professional interest. Regards, Bagerbrød Regards, Bagerbrød·1 päivä sittenIf Bioporto meets deadlines, then it's up to the FDA. Fortunately, it will be an advantage for Bioporto that the NGAL test for children is the benchmark for future AKI tests, so for that reason, the adult test will be approved much faster than the children's test was.·1 päivä sitten · Muokattu3D Do you live in your alternative world? If BP meets deadlines? When BP doesn't meet a deadline, a new deadline comes, which may or may not be met. When the budget is not met, a new budget comes, which may be met. In 2025, we got 3 new "budgets" because the original expectations didn't hold water. 2 downward adjustments of financial targets. In 2024, it was said that the adult test should be sent for approval in 2026. In 2025, the target was then changed to "application in 2027". Will 2026 end with another downward adjustment of financial targets? Will there be another share issue, even though it's "taboo" in here among the BP faithful? We have hardly seen the last "delay".
- ·3 päivää sitten2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He has bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl took office on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his appointment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.
- ·6.3.Dear Bagerbrød I am a bit confused by your answer. I hold 30,000 pcs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 11 111 | - | - | ||
| 18 074 | - | - | ||
| 11 371 | - | - | ||
| 1 493 | - | - | ||
| 2 732 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
2025 Q3 -tulosraportti
113 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.3. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenThe NGAL test can now be used for an incredible number of different diseases, but research has also been conducted into whether the test can also be used for pregnant women. The result was positive. They emphasize in the article that it is very positive that the test can be used early in pregnancy. So when the test for adults becomes FDA approved, it will certainly also become a permanent part of treatment for pregnant women. https://pmc.ncbi.nlm.nih.gov/articles/PMC9708734/·12 t sittenIt is clear who owns and who does not own bioporto, a bit pathetic 😏·8 t sittencreos If you put aside the unsubstantiated angles, then I would like to participate in a factual debate. Let me know when you are ready.
- ·1 päivä sittenI just want to remind you that there is a webcast on March 26 at 10:30 AM. I guess a new CFO will be presented on this occasion. Even if you cannot attend when it is broadcast, you can still ask questions and watch it when you have time. Registration necessary. https://www.inderes.dk/videos/bioporto-praesentation-af-fy-2025-resultater
- ·2 päivää sittenDear Progression When we talk about a penny stock, news can result in explosive movements. So I still believe that BP's price has not been determined yet. A piece of news can trigger explosive price movements. That's why I'm up around 4 kr. within a year. The final price target - relatively! - I cannot comment on. But quite simply: IF! the adult test comes through, then we have a case that, age by age, generates increased revenues. A STUPID! estimate - if 1-22 years with the company's other revenues is around 45,000,000, then an adult approval - AS A STARTING POINT - will be an x5. AND - I AM NOT SURE ABOUT THIS: If the test is included in various studies/treatment paradigms, then there is probably no upper limit for value?! I have quite cautiously pointed to approx. 4,- kr. within a year. Because of PERSPECTIVE. And if that holds, then - quite easily - a lot will happen subsequently. WHAT BioPorto is worth right now and CAN!, can change very quickly. I have a calculation model behind this, but here are the more principal considerations. I will not encourage anyone to buy or sell - I just have a professional interest. Regards, Bagerbrød Regards, Bagerbrød·1 päivä sittenIf Bioporto meets deadlines, then it's up to the FDA. Fortunately, it will be an advantage for Bioporto that the NGAL test for children is the benchmark for future AKI tests, so for that reason, the adult test will be approved much faster than the children's test was.·1 päivä sitten · Muokattu3D Do you live in your alternative world? If BP meets deadlines? When BP doesn't meet a deadline, a new deadline comes, which may or may not be met. When the budget is not met, a new budget comes, which may be met. In 2025, we got 3 new "budgets" because the original expectations didn't hold water. 2 downward adjustments of financial targets. In 2024, it was said that the adult test should be sent for approval in 2026. In 2025, the target was then changed to "application in 2027". Will 2026 end with another downward adjustment of financial targets? Will there be another share issue, even though it's "taboo" in here among the BP faithful? We have hardly seen the last "delay".
- ·3 päivää sitten2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He has bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl took office on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his appointment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.
- ·6.3.Dear Bagerbrød I am a bit confused by your answer. I hold 30,000 pcs.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 11 111 | - | - | ||
| 18 074 | - | - | ||
| 11 371 | - | - | ||
| 1 493 | - | - | ||
| 2 732 | - | - |
Välittäjätilasto
Dataa ei löytynyt